The company said that Health Canada’s target is to complete review within 300 days for 90% of submissions.
Vivian Liu, president and CEO of NexMed, said: “We are very pleased to reach another regulatory milestone. The acceptance of the NDS for review is a positive development for the discussions with potential commercialization partners in Canada.”